Langerhans Cell Histiocytosis in Children
On this page
Direct answer
Langerhans cell histiocytosis (LCH) is a clonal proliferation of myeloid dendritic cells — the epidermal Langerhans cell lineage — that infiltrates bone, skin, pituitary-hypothalamic axis, marrow, liver, spleen, lung and lymph nodes in single-system or multisystem patterns. Pathology shows Birbeck granules (the racquet-shaped tennis-racket organelles) on electron microscopy and CD1a with S100 positivity on immunohistochemistry — the defining triad of the diagnosis. The clinical pictures that recur in exams are the punched-out lytic skull lesion, the treatment-refractory seborrhoeic diaper or scalp rash, and central diabetes insipidus with a thickened pituitary stalk on MRI. Prognosis and treatment intensity hinge on whether "risk organs" (liver, spleen, marrow) are involved: single-system disease may need only local therapy, while multisystem disease receives vinblastine plus prednisolone-based chemotherapy, with cytarabine and cladribine-based regimens for refractory disease and BRAF V600E inhibitors an emerging targeted option.
What you must remember
- Cell and markers: clonal dendritic (Langerhans) cells, CD1a-positive, S100-positive, with Birbeck granules on electron microscopy — the two immunostains plus the granule make the diagnosis examinable.
- Bone disease: the commonest site, skull the classic bone — punched-out lytic lesions giving a temporal mass, mastoid destruction mimicking otitis media, or loose mandibular teeth (floating teeth); spine lesions risk collapse.
- Skin patterns: seborrhoeic dermatitis-like rash of scalp, diaper area, axillae and behind the ears, classically with petechiae within the lesions — a "refractory diaper rash with petechiae" stem is LCH in disguise; neonatal self-healing histiocytosis also occurs.
- Endocrine anchor: central diabetes insipidus is the commonest endocrine manifestation (thickened enhancing pituitary stalk on MRI); anterior pituitary failure with growth hormone deficiency may follow — image the stalk in any LCH child with polyuria.
- Risk organs decide prognosis: liver (dysfunction, hypoalbuminaemia), spleen (massive), marrow (cytopenias) mark high-risk multisystem disease with worse survival; isolated bone, skin or lung disease is lower-risk.
- Treatment ladder: single bone lesion — curettage, intralesional corticosteroid or observation; multisystem — weekly vinblastine plus prednisolone (the international trial backbone), salvaged by cytarabine or cladribine; BRAF V600E opens targeted therapy.
- Named eponyms still asked: eosinophilic granuloma (single-system bone), Hand-Schüller-Christian triad of diabetes insipidus, exophthalmos and lytic skull lesions, Letterer-Siwe disease (fulminant multisystem of infancy) — know them as historical patterns, but answer in modern single-system/multisystem language.
- Late effects clinic: endocrine follow-up of growth and puberty, hearing, orthopaedic surveillance, rare neurodegeneration, and secondary malignancy screening.
From rash to staging: how the case unfolds
Take a 20-month-old referred for a scaly, sometimes bleeding diaper rash unresponsive to three months of steroids and antifungals, with a new soft lump above the right ear and polydipsia waking the family hourly. Biopsy the rash — non-specific dermatitis is the commonest referral error in LCH, and histology with CD1a positivity converts "difficult eczema" into an oncology workup. Skull radiograph or CT shows a sharply lytic lesion; water-deprivation testing with inappropriately dilute urine proves diabetes insipidus, and MRI shows the thickened, enhancing stalk. Staging decides intensity: blood counts (marrow), liver function with albumin, spleen size, and a skeletal survey or whole-body MRI — this child has skin, bone and pituitary disease but no risk-organ involvement: multisystem low-risk. Therapy is one year of vinblastine with prednisolone per current protocols; diabetes insipidus is treated with desmopressin and usually persists for life — set that expectation early. Response at six weeks separates responders from non-responders, who escalate to cytarabine or cladribine. Follow-up covers growth (growth hormone deficiency screening), repeat bone imaging, audiology if the temporal bone was involved, and endocrine surveillance, because LCH relapses in a substantial minority and the family should hear "chronic disease with high cure chances".
Where students slip
The diagnosis is missed at the skin: any infant with recalcitrant seborrhoeic diaper rash with petechiae deserves a biopsy — examiners embed exactly that stem. Second, quoting the eponyms as modern entities; current stratification is single-system versus multisystem with risk-organ status, and answers should use that vocabulary. Third, central diabetes insipidus may be the presenting complaint with a stalk lesion on MRI, and chemotherapy rarely reverses it — desmopressin is started while the systemic disease is treated.
Frequently asked questions
What defines Langerhans cell histiocytosis pathologically?
Infiltration by clonal CD1a- and S100-positive dendritic cells containing Birbeck granules on electron microscopy — the racquet-shaped cytoplasmic organelles specific to Langerhans cells.
Which is the commonest endocrine manifestation of LCH?
Central diabetes insipidus, from hypothalamic-pituitary infiltration, typically with a thickened enhancing stalk on MRI; desmopressin treats it, but established disease rarely reverses with chemotherapy.
What are risk organs and why do they matter?
Liver, spleen and bone marrow — involvement defines high-risk multisystem disease with substantially worse prognosis and dictates systemic chemotherapy intensity.
How is single-system bone LCH treated?
Observation, curettage or intralesional corticosteroids often suffice for a single accessible lesion, with radiotherapy rarely; multisystem disease needs vinblastine-prednisolone-based chemotherapy.
Which molecular target is changing LCH therapy?
BRAF V600E, present in a majority of lesions in some paediatric series — BRAF inhibitors offer targeted therapy for refractory or multisystem disease.